SCHEMBL3906145

SCHEMBL3906145

O=c1[nH]n(Cc2ccc(F)cc2Cl)c2ccc(NS(=O)(=O)c3cccc(OC(F)F)c3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 6/20 0.39
BRD4 O60885 2/20 0.39
MAP2K7 O14733 1/20 0.37
PGR P06401 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
KIT P10721 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGER3 P43115 1/20 0.36
PKM P14618 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907047 0.90 BRAF (0.44) MAP2K4PGRHDAC3HDAC4HDAC1
SCHEMBL3909056 0.90 BRD4 (0.40) MAP2K4BRD4MAP2K7PGRHDAC3
SCHEMBL3906679 0.86 SERPINE1 (0.41) BRD4PGRHDAC3HDAC4HDAC1
SCHEMBL3916133 0.82 BRD4 (0.42) MAP2K4BRD4MAP2K7PGRHDAC3
SCHEMBL1818816 0.80 PTGES2 (0.42) BRD4PGRALDH1A1
SCHEMBL3907924 0.79 TP53 (0.44) KMT2A
SCHEMBL3903978 0.79 GSPT1 (0.41) BRD4KMT2APKM
SCHEMBL4540841 0.79 NR1I2 (0.47) BRD4HDAC1HTTALDH1A1
SCHEMBL1816688 0.78 PTGDR2 (0.44) MAP2K4PTGDR2KMT2APKMHTT
SCHEMBL3904637 0.77 BRD4 (0.50) MAP2K4BRD4PGRKITKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
EP-1797042-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2007-06-20 EP disclosed
WO-2006034804-A1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-04-06 WO disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 MAP2K4 2943/4885BRD4 2606/4885MAP2K7 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.